Abcl stock forecast.

At the close of trading, the stock’s price was $4.50, to imply an increase of 1.58% or $0.07 in intraday trading. The ABCL share’s 52-week high remains $14.15, putting it -214.44% down since that peak but still an impressive 14.0% since price per share fell to its 52-week low of $3.87.

Abcl stock forecast. Things To Know About Abcl stock forecast.

Over the past year, ABCL has underperformed the S&P 500, with a price decline of 28.37% against the S&P 500's growth of 17.07%. Data by YCharts. ABCL's market cap stands at $2.07B, with total debt ...The average twelve-month price prediction for AbCellera Biologics is $21.88 with a high price target of $34.00 and a low price target of $12.00. Learn more on ABCL's analyst rating history. Do Wall Street analysts like AbCellera Biologics more than its competitors? View AbCellera Biologics Inc ABCL investment & stock information. Get the latest AbCellera Biologics Inc ABCL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.AbCellera ( NASDAQ: ABCL) listed on the Nasdaq in December 2020, completing a monstrous initial public offering of 24.15m shares at a price of $20 per share, for funds of ~$483m, which would be ...

Dec 1, 2023 · According to 10 stock analysts, the average 12-month stock price forecast for NIO Inc. stock is $12.44, which predicts an increase of 73.99%. The lowest target is $8.00 and the highest is $18. On average, analysts rate NIO Inc. stock as a buy. The 8 analysts offering 1 year price forecasts for ABCL have a max estimate of — and a min estimate of —. Analyst rating Based on 9 analysts giving stock ratings to ABCL in the past 3 months.VIE : 53.01 (unch) AbCellera Biologics (ABCL) Q2 2023 Earnings Call Transcript Motley Fool - Fri Aug 4, 12:00AM CDT. ABCL earnings call for the period ending June 30, 2023. ABCL : 4.18 (-5.00%) AbCellera Biologics (ABCL) Q1 2023 Earnings Call Transcript Motley Fool - Thu May 4, 11:30PM CDT.

Previous Close $4.4. Volume 1.91M. Average Volume (3M) 1.64M. Market Cap. $1.28B. Enterprise Value $1.28B. Total Cash (Recent Filing) $795.69K. Total Debt (Recent Filing) $84.03K. Price to Earnings (P/E) -9.8.

AbCellera Biologics Inc. company earnings calendar and analyst expectations - Upcoming and past events | Nasdaq: ABCL | NasdaqAbcellera Biologics earnings beat by $0.11, revenue fell short of estimates. By Investing.com. • Aug 03, 2023. Investing.com - Abcellera Biologics (NASDAQ: ABCL) reported second quarter EPS of ...52-Week Range $3.87 - $14.97. Previous Close $4.4. Volume 1.91M. Average Volume (3M) 1.64M. Market Cap. $1.28B. Enterprise Value $1.28B. Total Cash (Recent Filing) $795.69K. Total Debt (Recent Filing) $84.03K.According to our current ABCL stock forecast, the value of AbCellera Biologics shares will drop by -6.13% and reach $ 4.40 per share by December 6, 2023. …

Recursion Pharmaceuticals Inc. 6.87. -0.18. -2.55%. Get Abcellera Biologics Inc (ABCL:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

Find real-time AB - AllianceBernstein Holding LP stock quotes, company profile, news and forecasts from CNN Business.

VIE : 53.01 (unch) AbCellera Biologics (ABCL) Q2 2023 Earnings Call Transcript Motley Fool - Fri Aug 4, 12:00AM CDT. ABCL earnings call for the period ending June 30, 2023. ABCL : 4.18 (-5.00%) AbCellera Biologics (ABCL) Q1 2023 Earnings Call Transcript Motley Fool - Thu May 4, 11:30PM CDT.Their ACN share price targets range from $279.00 to $410.00. On average, they anticipate the company's stock price to reach $337.26 in the next year. This suggests that the stock has a possible downside of 0.2%. View analysts price targets for ACN or view top-rated stocks among Wall Street analysts.AbCellera Biologics Inc. (ABCL 4.21%) Q4 2021 Earnings Call Feb 24, 2022, 5:00 p.m. ET Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Ladies and ...More than 80 oyster farms on the NSW South Coast remain closed after severe storms and flooding hit this week. It's a flip of the coin as to whether they'll be open in …2,065.00 -2.10(-0.10%) AbCellera Biologics Inc. (ABCL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 4.7800 +0.0500 (+1.06%) At close: 04:00PM EST 4.7600 -0.02 (-0.42%)... The average stock forecast for Abcellera Biologics Inc (ABCL) is 22.44 USD. This price target corresponds to an upside of 364.60%. The range of stock forecasts for ABCL is …

Hi Fellas, What do you think ABCL at < $6 per share. I already own this share as 60% of the portfolio and my average price is $8. I really like this stock because of the partnership model and the number of bets they have ~ 140 program. I am long term investor and want to hold this until 2028, provided i get somewhere between 5X to 10X return.Analyst Forecast. According to 41 analysts, the average rating for NVDA stock is "Strong Buy." The 12-month stock price forecast is $609.89, which is an increase of 30.42% from the latest price.Their ACN share price targets range from $279.00 to $410.00. On average, they anticipate the company's stock price to reach $337.26 in the next year. This suggests that the stock has a possible downside of 0.2%. View analysts price targets for ACN or view top-rated stocks among Wall Street analysts.ABCL stock recorded 16/30 (53%) green days with 5.07% price volatility over the last 30 days. Based on our AbCellera Biologics stock forecast, it's now a bad time to buy ABCL stock because it's trading 6.53% above our forecast. Disclaimer: This is not investment advice. The information provided is for general information purposes only.AbCellera Biologics (ABCL) Risk Factors. Public companies are required to disclose risks that can affect the business and impact the stock. These disclosures are known as “Risk Factors”. Companies disclose these risks in their yearly (Form 10-K), quarterly earnings (Form 10-Q), or “foreign private issuer” reports (Form 20-F).52-Week Range $3.87 - $14.97. Previous Close $4.4. Volume 1.91M. Average Volume (3M) 1.64M. Market Cap. $1.28B. Enterprise Value $1.28B. Total Cash (Recent Filing) $795.69K. Total Debt (Recent Filing) $84.03K.

13 sept 2023 ... ABCL stock has a median price target of 28.00, with a high estimate of 34.00 and a low estimate of 12.00, indicating potential for substantial ...Abcellera Biologics earnings beat by $0.11, revenue fell short of estimates. By Investing.com. • Aug 03, 2023. Investing.com - Abcellera Biologics (NASDAQ: ABCL) reported second quarter EPS of ...

Dec 1, 2023 · ABCL Earnings Date and Information. AbCellera Biologics last issued its quarterly earnings data on November 2nd, 2023. The reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.04. The business earned $6.60 million during the quarter, compared to the consensus estimate of $11.92 million. Are you tired of spending countless hours manually tracking your inventory? Are you looking for a way to improve your decision making and forecasting processes? Look no further than a free inventory tracking template.ABCL - Cup & Handle Breakout Trade Abcellera Biologics is a biotech stock setting up in a textbook cup with handle pattern. The stock has growing institutional sponsorship as shown in the chart from MarketSmith on the chart. It also has a relative strength ranking of 97/100. Shares formed a cup with a 37% depth and have since driftAbcellera ...Find real-time AB - AllianceBernstein Holding LP stock quotes, company profile, news and forecasts from CNN Business.Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.A $14.3 billion market cap divided by 330 million shares outstanding equals a valuation of $43.33 per share. Discounting a year 2030, $43.33 valuation, using a 10% discount rate gives us a present ...ABCL Forecast 2023. Check the latest forecasts. Read charts, analyst ratings, dividend and earningsView %COMPANY_NAME% ABC investment & stock information. Get the latest %COMPANY_NAME% ABC detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.52-Week Range $3.87 - $14.97. Previous Close $4.4. Volume 1.91M. Average Volume (3M) 1.64M. Market Cap. $1.28B. Enterprise Value $1.28B. Total Cash (Recent Filing) $795.69K. Total Debt (Recent Filing) $84.03K.

We don't have any Insights for this stock currently. Aditya Birla Cap. Share Price Returns. 1 Day, 1.67%. 1 Month ...

Analyst Forecast. According to 34 analysts, the average rating for TSLA stock is "Hold." The 12-month stock price forecast is $238.87, which is an increase of 1.45% from the latest price.

Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.AMC Entertainment Holdings, Inc. Class A Common Stock. $5.11 +0.02 +0.39%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation ...PLTR Stock 12 Months Forecast. Based on 15 Wall Street analysts offering 12 month price targets for Palantir Technologies in the last 3 months. The average price target is $14.67 with a high forecast of $25.00 and a low forecast of $5.00. The average price target represents a -23.59% change from the last price of $19.20.See the latest AbCellera Biologics Inc Ordinary Shares stock price (ABCL:XNAS), related news, valuation, dividends and more to help you make your investing decisions.The average twelve-month price prediction for AbCellera Biologics is $21.88 with a high price target of $34.00 and a low price target of $12.00. Learn more on ABCL's analyst rating history. Do Wall Street analysts like AbCellera Biologics more than its competitors?View %COMPANY_NAME% ABC investment & stock information. Get the latest %COMPANY_NAME% ABC detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.AbCellera Biologics Inc. Stock Forecast NASDAQ Stock Exchange > Healthcare > Biotechnology Open Broker Account $4.43 +0 (+0%) At Close: Nov 24, …ABCL Stock Analysis: Impressive Performance and Optimistic Analyst Forecasts ABCL stock had an impressive performance on September 20, 2023, based on the information provided. The 7 analysts offering 12-month price forecasts for Abcellera Biologics Inc have a median target of 28.00, with a high estimate of 34.00 and a low estimate of 12.00.AbCellera Biologics Stock Forecast. Is AbCellera Biologics Stock Undervalued? The current AbCellera Biologics [ ABCL] share price is $4.47. The Score for ABCL is 41, which is 18% below its historic median score of 50, and infers higher risk than normal. ABCL is currently trading in the 40-50% percentile range relative to its historical Stock ... Previous Close $4.4. Volume 1.91M. Average Volume (3M) 1.64M. Market Cap. $1.28B. Enterprise Value $1.28B. Total Cash (Recent Filing) $795.69K. Total Debt (Recent Filing) $84.03K. Price to Earnings (P/E) -9.8.

AbCellera Biologics Inc. research and ratings by Barron's. View ABCL revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.Previous Close $4.4. Volume 1.91M. Average Volume (3M) 1.64M. Market Cap. $1.28B. Enterprise Value $1.28B. Total Cash (Recent Filing) $795.69K. Total Debt (Recent Filing) $84.03K. Price to Earnings (P/E) -9.8.ABCL Stock Performance: A Look at May 26, 2023. On May 26, 2023, Abcellera Biologics Inc (ABCL) saw a significant increase in its stock price, with shares trading at $28.00, up 306.39% from the previous day’s closing price. This surge in price can be attributed to the positive outlook of the 9 analysts who offer 12-month price forecasts for ABCL.Instagram:https://instagram. hedge fund stocksstocktwits fiskerunusual whales etfswill heating oil prices go down Stock Price Forecast. According to 6 stock analysts, the average 12-month stock price forecast for ABCL stock stock is $22.33, which predicts an increase of …Find the latest Bristol-Myers Squibb Company (BMY) stock quote, history, news and other vital information to help you with your stock trading and investing. td ameritrade day trading accountbest mortgage rates in tn The average twelve-month price prediction for AbCellera Biologics is $21.88 with a high price target of $34.00 and a low price target of $12.00. Learn more on ABCL's analyst rating history. Do Wall Street analysts like AbCellera Biologics more than its competitors? macy sstock Over the past year, ABCL has underperformed the S&P 500, with a price decline of 28.37% against the S&P 500's growth of 17.07%. Data by YCharts. ABCL's market cap stands at $2.07B, with total debt ...View 8 reports from 3 analysts offering long term price targets for Aditya Birla Capital Ltd.. Aditya Birla Capital Ltd. has an average target of 205.67. The consensus estimate represents an upside of 21.05% from the last price of 169.90. Reco - This broker has downgraded this stock from it's previous report.